Table 2.
Antibiotics used for empirical and definitive therapy among the patients.
| Variable | Frequency (%) |
|---|---|
| Empirical antibiotics (n = 235) | |
| Meropenem | 58 (24.7) |
| Piperacillin-tazobactam | 48 (20.4) |
| Vancomycin | 19 (8.1) |
| Colistin | 13 (5.5) |
| Cotrimoxazole | 11 (4.7) |
| Ciprofloxacin | 11 (4.7) |
| Ceftriaxone | 11 (4.7) |
| Cefuroxime | 10 (4.3) |
| Amoxicillin-clavulanic acid | 8 (3.4) |
| Metronidazole | 8 (3.4) |
| Cefepime | 7 (3.0) |
| Ampicillin-sulbactam | 6 (2.6) |
| Ceftazidime | 5 (2.1) |
| Azithromycin | 5 (2.1) |
| Cloxacillin | 4 (1.7) |
| Amikacin | 3 (1.3) |
| Clindamycin | 3 (1.3) |
| Imipenem | 2 (0.9) |
| Fusidic acid | 1 (0.4) |
| Ertapenem | 1 (0.4) |
| Cefoperazone | 1 (0.4) |
| Combination empirical antibiotic therapy | 55 (37.9) |
| Received active empirical antibiotics | 16 (11.0) |
| Received active antibiotic treatment | 87 (60.0) |
| Received active antibiotic treatment in first 48 h | 21 (14.5) |
| Definitive antibiotics (n = 109) | |
| Colistin | 69 (63.3) |
| Amikacin | 9 (8.3) |
| Meropenem | 6 (5.5) |
| Piperacillin-tazobactam | 6 (5.5) |
| Gentamicin | 5 (4.6) |
| Ceftazidime | 4 (3.7) |
| Cotrimoxazole | 3 (2.8) |
| Ciprofloxacin | 3 (2.8) |
| Cefepime | 2 (1.8) |
| Imipenem | 2 (1.8) |
| Combination definitive antibiotic therapy | 62 (42.8) |
| Types of combinations | |
| Colistin-based combinations | 47 (75.8) |
| Non-colistin-based combinations | 15 (24.2) |
| Mean days to effective antibiotics | 4.6 ± 3.3 |